This study is for people with endometrial cancer (EC) who have already tried platinum-based chemotherapy and immunotherapy. **Platinum-based chemotherapy** uses a metal to help kill cancer cells, and **immunotherapy** helps your body’s immune system fight cancer. The research compares a new treatment called **MK-2870 sacituzumab tirumotecan** with regular chemotherapy to see if the new treatment helps people live longer and keeps the cancer from worsening. To join this study, you must have a confirmed diagnosis of certain types of EC and have already tried some treatments. You cannot join if you have other certain illnesses or if you have had too many different treatments before.

• The study compares MK-2870 to chemotherapy to see which works better.
• You need to have tried specific past treatments to qualify.
• Some health issues or treatments make you ineligible.